IMPROVED EFFICACY AFTER INCORPORATING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) INTO KRD TREATMENT WITH CARFILZOMIB (CFZ), LENALIDOMIDE (LEN), AND DEXAMETHASONE (DEX) IN NEWLY DIAGNOSED MULTIPLE MYELOMA

被引：0
|
作者：
Jakubowiak, A. [1 ]
Raje, N. [2 ]
Vij, R. [3 ]
Reece, D. [4 ]
Berdeja, J. [5 ]
Vesole, D. [6 ]
Jagannath, S. [7 ]
Cole, C. [8 ]
Faham, M. [9 ]
Nam, J. [1 ]
Stephens, L. [1 ]
Severson, E. [1 ]
Revethis, A. [1 ]
Wolfe, B. [1 ]
Rosebeck, S. [1 ]
Gurbuxani, S. [1 ]
Rosenbaum, C. [1 ]
Jasielec, J. [10 ]
Dytfeld, D. [11 ]
Griffith, K. [8 ]
Zimmerman, T. [1 ]
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Massachussetts Gen Hosp, Boston, MA USA
[3] Washington Univ, St Louis, MO USA
[4] Princess Margaret Canc Ctr, Toronto, ON, Canada
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] John Theurer Canc Ctr, Hackensack, NJ USA
[7] Mt Sinai Med Ctr, New York, NY 10029 USA
[8] Univ Michigan, Ann Arbor, MI 48109 USA
[9] Adapt Biotechnol, Seattle, WA USA
[10] Northshore Univ Hlth Syst, Evanston, IL USA
[11] NJ Univ Med Sci, Poznan, Poland
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S101
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [1] Carfilzomib (CFZ, Kyprolis®), Lenalidomide (LEN, Revlimide®), and Dexamethasone (DEX) (KRd) Combined with Autologous Stem Cell Transplant (ASCT) Shows Improved Efficacy Compared with Krd without ASCT in Newly Diagnosed Multiple Myeloma (NDMM)
    Zimmerman, Todd M.
    Griffith, Kent
    Jasielec, Jagoda K.
    Rosenbaum, Cara A.
    Berdeja, Jesus G.
    Vij, Ravi
    Raje, Noopur
    Reece, Donna E.
    Vesole, David H.
    Jagannath, Sundar
    Kaminski, Mark
    Cole, Craig
    Nam, Jennifer
    Stephens, Leonor A.
    Rosebeck, Shaun
    Gurbuxani, Sandeep
    Dytfeld, Dominik
    Jakubowiak, Andrzej J.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S40 - S40
  • [2] Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).
    Zimmerman, Todd M.
    Griffith, Kent A.
    Jasielec, Jagoda
    Rosenbaum, Cara Ann
    McDonnell, Kathryn
    Waite-Marin, Jessica
    Berdeja, Jesus G.
    Raje, Noopur S.
    Reece, Donna Ellen
    Vij, Ravi
    Alonge, Mattina
    Rosebeck, Shaun
    Gurbuxani, Sandeep
    Faham, Malek
    Kong, Katherine A.
    Levy, Joan
    Jakubowiak, Andrzej J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] EXTENDED TREATMENT WITH THE COMBINATION OF CARFILZOMIB (CFZ), LENALIDOMIDE (LEN), AND DEXAMETHASONE ( DEX) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
    Jakubowiak, A.
    Griffith, K.
    Dytfeld, D.
    Vesole, D.
    Jagannath, S.
    Anderson, T.
    Nordgren, B.
    Detweiler-Short, K.
    Lebovic, D.
    Stockerl-Goldstein, K.
    Jobkar, T.
    Wear, S.
    Al-Zoubi, A.
    Ahmed, A.
    Mietzel, M.
    Couriel, D.
    Kaminski, M.
    Hussein, M.
    Yeganegi, H.
    Vij, R.
    [J]. HAEMATOLOGICA, 2012, 97 : 115 - 115
  • [4] Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)
    Zimmerman, Todd
    Raje, Noopur S.
    Vij, Ravi
    Reece, Donna
    Berdeja, Jesus G.
    Stephens, Leonor A.
    McDonnell, Kathryn
    Rosenbaum, Cara A.
    Jasielec, Jagoda
    Richardson, Paul G.
    Gurbuxani, Sandeep
    Nam, Jennifer
    Severson, Erica
    Wolfe, Brittany D.
    Rosebeck, Shaun
    Stefka, Andrew
    Dytfeld, Dominik
    Griffith, Kent
    Jakubowiak, Andrzej
    [J]. BLOOD, 2016, 128 (22)
  • [5] Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX).
    Jakubowiak, Andrzej J.
    Griffith, Kent A.
    Dytfeld, Dominik
    Vesole, David H.
    Jagannath, Sundar
    Anderson, Tara B.
    Nordgren, Brian K.
    Detweiler-Short, Kristen
    Lebovic, Daniel
    Stockerl-Goldstein, Keith
    Jobkar, Terri L.
    Wear, Sandra Marija
    Al-Zoubi, Ammar
    Ahmed, Asra Z.
    Mietzel, Melissa A.
    Couriel, Daniel R.
    Kaminski, Mark Stefan
    Hussein, Mohamad A.
    Yeganegi, Homa
    Vij, Ravi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
    Jasielec, Jagoda K.
    Kubicki, Tadeusz
    Raje, Noopur
    Vij, Ravi
    Reece, Donna
    Berdeja, Jesus
    Derman, Benjamin A.
    Rosenbaum, Cara A.
    Richardson, Paul
    Gurbuxani, Sandeep
    Major, Sarah
    Wolfe, Brittany
    Stefka, Andrew T.
    Stephens, Leonor
    Tinari, Kathryn M.
    Hycner, Tyler
    Rojek, Alexandra E.
    Dytfeld, Dominik
    Griffith, Kent A.
    Zimmerman, Todd M.
    Jakubowiak, Andrzej J.
    [J]. BLOOD, 2020, 136 (22) : 2513 - 2523
  • [7] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Derkach, Andriy
    Nemirovsky, David
    Ciardiello, Amanda
    Diamond, Benjamin
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Maclachlan, Kylee
    Patel, Dhwani
    Lahoud, Oscar B. B.
    Landau, Heather J. J.
    Chung, David J. J.
    Shah, Gunjan L. L.
    Scordo, Michael
    Giralt, Sergio A. A.
    Lesokhin, Alexander
    Usmani, Saad Z. Z.
    Landgren, Ola
    Korde, Neha
    [J]. BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [8] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Carlyn Rose Tan
    Andriy Derkach
    David Nemirovsky
    Amanda Ciardiello
    Benjamin Diamond
    Malin Hultcrantz
    Hani Hassoun
    Sham Mailankody
    Urvi Shah
    Kylee Maclachlan
    Dhwani Patel
    Oscar B. Lahoud
    Heather J. Landau
    David J. Chung
    Gunjan L. Shah
    Michael Scordo
    Sergio A. Giralt
    Alexander Lesokhin
    Saad Z. Usmani
    Ola Landgren
    Neha Korde
    [J]. Blood Cancer Journal, 13
  • [9] POST-TRANSPLANT CARFILZOMIB (KYPROLIS®), LENALIDOMIDE (REVLIMID®), AND DEXAMETHASONE (KRD) CONSOLIDATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): EFFICACY AND TOLERABILITY OF EXTENDED TREATMENT
    Jakubowiak, A.
    Griffith, K.
    Jasielec, J.
    Rosenbaum, C.
    McDonnell, K.
    Berdeja, J.
    Vij, R.
    Raje, N.
    Reece, D.
    Dytfeld, D.
    Zimmerman, T.
    [J]. HAEMATOLOGICA, 2015, 100 : 312 - 312
  • [10] INITIAL RESULTS FROM A PHASE 2 STUDY OF CARFILZOMIB, LENALIDOMIDE, AND LOW-DOSE DEXAMETHASONE (KRD) PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
    Zimmerman, T. M.
    Griffith, K.
    Jasielec, J. K.
    Rosenbaum, C. A.
    McDonnell, K.
    Marin, J.
    Bakker, J.
    Berdeja, J. G.
    Vij, R.
    Jakubowiak, A. J.
    [J]. HAEMATOLOGICA, 2014, 99 : 103 - 103
12345